Literature DB >> 26009261

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

Yi-Bin Chen1, Shuli Li2, David C Fisher3, Jessica Driscoll4, Candice Del Rio4, Jeremy Abramson4, Philippe Armand3, Jeffrey Barnes4, Jennifer Brown3, Corey Cutler3, Areej El-Jawahri4, Vincent T Ho3, Ephraim Hochberg4, Steven McAfee4, Ronald Takvorian4, Thomas R Spitzer4, Joseph H Antin3, Robert Soiffer3, Eric Jacobsen3.   

Abstract

Many patients with lymphoma relapse after autologous stem cell transplantation (AutoSCT). These patients are often considered for allogeneic stem cell transplantation (AlloSCT) if remission can be achieved. If a tandem approach was organized, some cases of relapse might be prevented. We conducted a phase II trial of tandem AutoSCT followed by reduced-intensity conditioning (RIC) AlloSCT for patients with high-risk lymphoma. High-dose chemotherapy was given with busulfan, cyclophosphamide, and etoposide. AlloSCT was composed of RIC with busulfan/fludarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Donors were fully matched related or unrelated donors. AlloSCT was performed any time between 40 days and 6 months after AutoSCT. Forty-two patients were enrolled, and all patients underwent AutoSCT. RIC AlloSCT was performed in 29 patients. In the 29 patients who underwent tandem transplant, median time from AutoSCT to AlloSCT was 96 days (range, 48 to 169). The 6-month cumulative incidence of grades II to IV acute GVHD was 13.8% (90% confidence interval [CI], 5.3% to 26.3%). Cumulative incidence of chronic GVHD at 1 year was 37.9% (90% CI, 23.1% to 52.7%). Nonrelapse mortality at 2 years after AlloSCT was 11.1% (90% CI, 3.5% to 23.6%). At a median follow-up of 30 months (range, 17.1 to 51.5) for the entire group, the 2-year progression-free survival rate was 64% (90% CI, 50% to 75%) and the 2-year overall survival rate was 69% (90% CI, 43% to 85%). For the 29 patients who underwent tandem SCT, the 2-year progression-free survival rate was 72% (90% CI, 55% to 83%) and the 2-year OS rate was 89% (90% CI, 74% to 96%). Tandem AutoSCT-RIC AlloSCT appears to be safe and effective in patients with high-risk lymphoma. Prospective trials using such an approach in specific lymphoma subtypes are warranted.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Auto-allo; Lymphoma; Reduced-intensity conditioning; Tandem transplant

Mesh:

Substances:

Year:  2015        PMID: 26009261     DOI: 10.1016/j.bbmt.2015.05.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.

Authors:  Martin G Sauer; Peter J Lang; Michael H Albert; Peter Bader; Ursula Creutzig; Matthias Eyrich; Johann Greil; Bernd Gruhn; Wolfgang Holter; Thomas Klingebiel; Bernhard Kremens; Heiko von der Leyen; Christine Mauz-Körholz; Roland Meisel; Kirsten Mischke; Ingo Müller; Charlotte M Niemeyer; Christina Peters; Christine Pohler; Dirk Reinhardt; Birgit Burkhardt; Paul G Schlegel; Ansgar S Schulz; Johanna Schrum; Petr Sedlacek; Brigitte Strahm; Wilhelm Woessmann; Rupert Handgretinger; Martin Zimmermann; Arndt Borkhardt
Journal:  Leukemia       Date:  2019-10-02       Impact factor: 11.528

Review 2.  Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Authors:  Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

3.  Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.

Authors:  Koji Takaishi; Tomoya Muto; Naoya Mimura; Jun Takiguchi; Yuhei Nagao; Nagisa Oshima-Hasegawa; Shokichi Tsukamoto; Yusuke Takeda; Shio Mitsukawa; Masahiro Takeuchi; Chikako Ohwada; Satoshi Ota; Tohru Iseki; Chiaki Nakaseko; Emiko Sakaida
Journal:  Int J Hematol       Date:  2018-05-21       Impact factor: 2.490

Review 4.  Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.

Authors:  Yaya Chu; Aliza Gardenswartz; Amanda M Termuhlen; Mitchell S Cairo
Journal:  Br J Haematol       Date:  2019-01-06       Impact factor: 6.998

5.  Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Authors:  Christopher R Flowers; Luciano J Costa; Marcelo C Pasquini; Jennifer Le-Rademacher; Michael Lill; Tsiporah B Shore; William Vaughan; Michael Craig; Cesar O Freytes; Thomas C Shea; Mitchell E Horwitz; Joseph W Fay; Shin Mineishi; Damiano Rondelli; James Mason; Ira Braunschweig; Weiyun Ai; Rosa F Yeh; Tulio E Rodriguez; Ian Flinn; Terrance Comeau; Andrew M Yeager; Michael A Pulsipher; Isabelle Bence-Bruckler; Pierre Laneuville; Philip Bierman; Andy I Chen; Kazunobu Kato; Yanlin Wang; Cong Xu; Angela J Smith; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-31       Impact factor: 5.742

Review 6.  How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Authors:  Christian Gisselbrecht; Eric Van Den Neste
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.